Article

Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions

2026-07-23

Abstract excerpt

Structured Abstract Background Actionable oncogenic gene fusions involving ALK, ROS1, RET, NTRK, and NRG1 define distinct molecular subsets of advanced non-small cell lung cancer (NSCLC) that derive substantial benefit from fusion-directed targeted therapies. Although pivotal clinical trials have demonstrated impressive efficacy, comparative real-world outcomes across multiple actionable fusion subtypes remain lim...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b753e76b-ab71-536a-95b8-173c1c4a83fc
DOI: 10.20944/preprints202607.1726.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene FusionsDOI 10.20944/preprints202607.1726.v1Read

Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country.Semantic proximity Read

Comparison of actionable alterations in cancers with kinase fusion, mutation, and amplificationSemantic proximity Read

Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study.Semantic proximity Read

Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data.Semantic proximity Read

Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCSemantic proximity Read

Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non–Small Cell Lung CancerSemantic proximity Read

Lung Cancer: Targeted Therapy in 2025Semantic proximity Read

Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.Semantic proximity Read

Fusion‐positive non‐small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implicationsSemantic proximity Read

Targeted therapy in the treatment of lung cancer in Iceland 2010-2023.Semantic proximity Read

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.Semantic proximity Read

Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.Semantic proximity Read